※ 출처: ClinicalTrials.gov
총 341건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, NCT No, 개시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 NCT No 개시일자
1 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Endometrial Neoplasms Biological: pembrolizumab|Drug: carboplatin|Drug: paclitaxel|Drug: docetaxel|Drug: cisplatin Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Gynecologic Oncology Group Phase 3 NCT05173987 2022-02-03
2 A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease Crohn's Disease Drug: ABBV-154|Drug: Placebo AbbVie Phase 2 NCT05068284 2022-01-31
3 Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV Hepatitis Delta Virus Drug: Peginterferon Lambda-1a Eiger BioPharmaceuticals Phase 3 NCT05070364 2021-12-21
4 Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) Ovarian Cancer|Carcinoma, Ovarian Epithelial|Fallopian Tube Neoplasms Biological: Pembrolizumab|Drug: Paclitaxel|Drug: Bevacizumab|Other: Placebo for pembrolizumab|Drug: Docetaxel Merck Sharp & Dohme LLC Phase 3 NCT05116189 2021-12-13
5 Efficacy and Safety of GNR-038 vs Berinert짰 in Patients With Hereditary Angioedema Hereditary Angioedema Drug: GNR-038, 50 ??/ kg|Drug: GNR-038, 100 ??/ kg|Drug: Berinert짰, 20 ??/ kg|Drug: Placebo|Drug: GNR-038. The dose will be selected according to results of stage 1 clinical trial. AO GENERIUM Phase 2|Phase 3 NCT04898309 2021-12-01
6 A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure Carcinoma, Non-Small-Cell Lung Drug: Lazertinib|Drug: Amivantamab|Drug: Pemetrexed|Drug: Carboplatin Janssen Research & Development, LLC Phase 3 NCT04988295 2021-11-17
7 A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Primary Immune Thrombocytopenia Biological: efgartigimod PH20 SC argenx Phase 3 NCT04812925 2021-11-17
8 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) Colorectal Cancer Biological: favezelimab/pembrolizumab|Drug: regorafenib|Drug: TAS-102 Merck Sharp & Dohme LLC Phase 3 NCT05064059 2021-11-10
9 A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis Arthritis, Psoriatic Drug: Guselkumab|Drug: Golimumab|Drug: Placebo Janssen Research & Development, LLC Phase 2 NCT05071664 2021-10-25
10 A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Generalized Myasthenia Gravis Drug: Satralizumab|Other: Placebo Hoffmann-La Roche Phase 3 NCT04963270 2021-10-19

1 2 3 4 5 6 7 8 9 10

로그인회원가입 사이트맵고객지원법령/자료실